Table of contents
November 2007 Volume 4 No 11
Editorial
Viewpoint
Stereotactic radiotherapy for stage I non-small-cell lung cancer—the triumph of technology over biology?
614Should patients with stage I non-small-cell lung cancer who are unsuitable for surgery receive hypofractionated stereotactic radiotherapy? In the rush to implement new technology, there could be a danger of overlooking refinements important to ensure safety, according to the author of this Viewpoint.
doi:10.1038/ncponc0954 | Full Text | PDF (128K)
Research Highlights
EGFR status and expression of downstream kinases in colorectal tumors and metastatic sites
616Breast cancer death rates are similar in BRCA mutation carriers and noncarriers
616Liquid-based and conventional cytology are equivalent for cervical cancer screening
616doi:10.1038/ncponc0920 | Full Text | PDF (105K)
Development of rash indicates positive outcome in erlotinib-treated patients
617Poor results with intensified maintenance chemotherapy in acute promyelocytic leukemia
617doi:10.1038/ncponc0924 | Full Text | PDF (102K)
Study demonstrates that a history of eczema or hayfever reduces the risk of ALL in children
618Distinct patterns of recurrence in triple-negative breast tumors
618Distinct mutations of FLT3 result in different outcomes in patients with AML
619Low-dose radiation induces apoptotic and immunological responses in patients with FL
619Duplicated TMPRSS2–ERG fusion predicts extremely poor outcome in prostate cancer
619doi:10.1038/ncponc0943 | Full Text | PDF (104K)
Can a healthy diet reduce the risk of breast cancer recurrence?
620A novel treatment regimen for poor-prognosis or relapsed germ-cell tumors
620doi:10.1038/ncponc0947 | Full Text | PDF (101K)
Short-term use of rofecoxib increases the risk for adverse cardiovascular events
621Practice Points
Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin?
622doi:10.1038/ncponc0952 | Full Text | PDF (130K)
Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible
624doi:10.1038/ncponc0953 | Full Text | PDF (139K)
Aromatase inhibitors and tamoxifen: where do we go from here?
626doi:10.1038/ncponc0955 | Full Text | PDF (135K)
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer
628doi:10.1038/ncponc0936 | Full Text | PDF (132K)
Does computer-aided detection increase the accuracy of interpretation of mammograms?
630doi:10.1038/ncponc0963 | Full Text | PDF (134K)
Reviews
Will focal therapy become a standard of care for men with localized prostate cancer?
632The current choice for men with localized prostate cancer lies between active surveillance and radical therapy, but overtreatment associated with therapy poses a significant challenge. The authors of this Review propose a new concept whereby only the tumor focus and a margin of normal tissue are treated. The advantages and limitations of active surveillance and of radical therapy are reviewed, with focal therapy presented as a means for bridging these two approaches. With emerging techniques that can treat to millimeter accuracy, focal therapy of prostate cancer is now possible.
doi:10.1038/ncponc0959 | Full Text | PDF (845K)
Costs of cancer care in the USA: a descriptive review
643While many studies assessing the cost of cancer care have been conducted in the US, to date, these studies and the underlying methods used to estimate costs have not been reviewed systematically. The authors of this article conducted a descriptive review of the published literature on the cost of cancer care in the US, and discuss the implications of the heterogeneity of their findings.
doi:10.1038/ncponc0978 | Full Text | PDF (382K)
Surgery Insight: oncoplastic breast-conserving reconstruction—indications, benefits, choices and outcomes
657Techniques that combine the skills of resection with reconstruction have led to a third approach called oncoplastic breast-conserving reconstruction. Emerging data on the oncological and cosmetic outcomes of this technique confi rm the clinical utility of this new approach to the surgical management of patients with breast cancer, as discussed in this Review.
doi:10.1038/ncponc0957 | Full Text | PDF (481K)
Case Study
Radioactive iodine therapy in poorly differentiated thyroid cancer
665Poorly differentiated thyroid cancers (PDTCs) are usually aggressive tumors with high rates of recurrence and distant metastases that are often resistant to radioactive iodine therapy. Tuttle and colleagues present the case of a 55-year-old man who was diagnosed with metastatic PDTC and was managed with radioactive iodine therapy. The authors discuss the current management options for patients with PDTCs that are nonresponsive to RAI therapy and highlight the need for the discovery of new systemic treatments for these patients.
doi:10.1038/ncponc0979 | Full Text | PDF (276K)
Erratum
Book Reviews
Book review: Boyiadzis et al. (2007): Hematology-Oncology Therapy. New York: McGraw-Hill
E1doi:10.1038/ncponc0956 | Full Text
Book review: Abrahm JL (2005) A Physician's Guide to Pain and Symptom Management in Cancer Patients, edn 2. Baltimore: The Johns Hopkins University Press
E2doi:10.1038/ncponc0965 | Full Text
